368 related articles for article (PubMed ID: 12074689)
1. Pharmacokinetics of the carmustine implant.
Fleming AB; Saltzman WM
Clin Pharmacokinet; 2002; 41(6):403-19. PubMed ID: 12074689
[TBL] [Abstract][Full Text] [Related]
2. Sustainable release of carmustine from biodegradable poly[((D,L))-lactide-co-glycolide] nanofibrous membranes in the cerebral cavity: in vitro and in vivo studies.
Tseng YY; Liao JY; Chen WA; Kao YC; Liu SJ
Expert Opin Drug Deliv; 2013 Jul; 10(7):879-88. PubMed ID: 23289446
[TBL] [Abstract][Full Text] [Related]
3. Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.
Lin SH; Kleinberg LR
Expert Rev Anticancer Ther; 2008 Mar; 8(3):343-59. PubMed ID: 18366283
[TBL] [Abstract][Full Text] [Related]
4. Modeling mass transfer from carmustine-loaded polymeric implants for malignant gliomas.
Pereira DY; Yip AT; Lee BS; Kamei DT
J Lab Autom; 2014 Feb; 19(1):19-34. PubMed ID: 23975389
[TBL] [Abstract][Full Text] [Related]
5. The role of BCNU polymer wafers (Gliadel) in the treatment of malignant glioma.
Nagpal S
Neurosurg Clin N Am; 2012 Apr; 23(2):289-95, ix. PubMed ID: 22440872
[TBL] [Abstract][Full Text] [Related]
6. Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.
Shapira-Furman T; Serra R; Gorelick N; Doglioli M; Tagliaferri V; Cecia A; Peters M; Kumar A; Rottenberg Y; Langer R; Brem H; Tyler B; Domb AJ
J Control Release; 2019 Feb; 295():93-101. PubMed ID: 30605703
[TBL] [Abstract][Full Text] [Related]
7. Morphological characterization of polyanhydride biodegradable implant gliadel during in vitro and in vivo erosion using scanning electron microscopy.
Dang W; Daviau T; Brem H
Pharm Res; 1996 May; 13(5):683-91. PubMed ID: 8860422
[TBL] [Abstract][Full Text] [Related]
8. Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors.
Sipos EP; Tyler B; Piantadosi S; Burger PC; Brem H
Cancer Chemother Pharmacol; 1997; 39(5):383-9. PubMed ID: 9054951
[TBL] [Abstract][Full Text] [Related]
9. In vitro Study of Serial Changes to Carmustine Wafers (Gliadel) with MR Imaging and Computed Tomography.
Doishita S; Shimono T; Yoneda T; Yamada E; Tsukamoto T; Takemori D; Kimura D; Tatekawa H; Sakamoto S; Miki Y
Magn Reson Med Sci; 2018 Jan; 17(1):58-66. PubMed ID: 28867760
[TBL] [Abstract][Full Text] [Related]
10. Role of convective flow in carmustine delivery to a brain tumor.
Arifin DY; Lee KY; Wang CH; Smith KA
Pharm Res; 2009 Oct; 26(10):2289-302. PubMed ID: 19639394
[TBL] [Abstract][Full Text] [Related]
11. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience.
Attenello FJ; Mukherjee D; Datoo G; McGirt MJ; Bohan E; Weingart JD; Olivi A; Quinones-Hinojosa A; Brem H
Ann Surg Oncol; 2008 Oct; 15(10):2887-93. PubMed ID: 18636295
[TBL] [Abstract][Full Text] [Related]
12. Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain.
Brem H; Tamargo RJ; Olivi A; Pinn M; Weingart JD; Wharam M; Epstein JI
J Neurosurg; 1994 Feb; 80(2):283-90. PubMed ID: 8283268
[TBL] [Abstract][Full Text] [Related]
13. Brain tumor and Gliadel wafer treatment.
Panigrahi M; Das PK; Parikh PM
Indian J Cancer; 2011; 48(1):11-7. PubMed ID: 21330749
[TBL] [Abstract][Full Text] [Related]
14. Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma.
Giese A; Kucinski T; Knopp U; Goldbrunner R; Hamel W; Mehdorn HM; Tonn JC; Hilt D; Westphal M
J Neurooncol; 2004 Feb; 66(3):351-60. PubMed ID: 15015668
[TBL] [Abstract][Full Text] [Related]
15. Carmustine wafer implantation when surgical cavity is communicating with cerebral ventricles: technical considerations on a clinical series.
Della Puppa A; Rossetto M; Ciccarino P; Denaro L; Rotilio A; d'Avella D; Scienza R
World Neurosurg; 2011; 76(1-2):156-9; discussion 67-8. PubMed ID: 21839967
[TBL] [Abstract][Full Text] [Related]
16. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.
Westphal M; Hilt DC; Bortey E; Delavault P; Olivares R; Warnke PC; Whittle IR; Jääskeläinen J; Ram Z
Neuro Oncol; 2003 Apr; 5(2):79-88. PubMed ID: 12672279
[TBL] [Abstract][Full Text] [Related]
17. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas.
Brem H; Mahaley MS; Vick NA; Black KL; Schold SC; Burger PC; Friedman AH; Ciric IS; Eller TW; Cozzens JW
J Neurosurg; 1991 Mar; 74(3):441-6. PubMed ID: 1993909
[TBL] [Abstract][Full Text] [Related]
18. Excretion of a radiolabelled anticancer biodegradable polymeric implant from the rabbit brain.
Domb AJ; Rock M; Perkin C; Yipchuck G; Broxup B; Villemure JG
Biomaterials; 1995 Sep; 16(14):1069-72. PubMed ID: 8519927
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain.
Fung LK; Ewend MG; Sills A; Sipos EP; Thompson R; Watts M; Colvin OM; Brem H; Saltzman WM
Cancer Res; 1998 Feb; 58(4):672-84. PubMed ID: 9485020
[TBL] [Abstract][Full Text] [Related]
20. Polymeric drug delivery for the treatment of glioblastoma.
Wait SD; Prabhu RS; Burri SH; Atkins TG; Asher AL
Neuro Oncol; 2015 Mar; 17 Suppl 2(Suppl 2):ii9-ii23. PubMed ID: 25746091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
